Get the Daily Brief
Latest Biotech News
FDA regulatory approach for rare diseases
The FDA laid out a “Rare Disease Framework Initiative” aimed at reworking how the agency reviews rare disease therapies, shifting from one-size-fits-all standards toward condition-specific...
Rare-disease financing and clinical pipeline momentum
UK biotech OMass Therapeutics closed an oversubscribed $310 million Series C to advance its endocrinology and immunology programs, led by OMS1620 in Phase II for congenital adrenal hyperplasia and...
AI in regulatory science
FDA researchers unveiled ARTEMIS, a framework designed to turn thousands of monoclonal antibody papers into compact, steerable “AI memory” for regulatory science. In reported benchmarks, ARTEMIS...
Protein drug design collaboration for metabolic disease
Zealand Pharma signed a multi-target collaboration with Generate Biomedicines to design protein therapeutics for obesity and other metabolic diseases using Generate’s AI platform. Zealand will...
Cell therapy revival under new management
Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, took control of the cell therapies the company divested during a strategic overhaul and rebranded as Lakefront...
VXRD pipeline: gene-directed Alzheimer’s protein suppression
Arrowhead Pharmaceuticals reported early-stage human data for ARO-MAPT, an RNA interference medicine intended to lower tau in the central nervous system. The company said the highest dose reduced...
Device-era antimicrobial resistance threat in hospitals
Surveillance data show Candida auris clinical cases more than doubled from 2,882 in 2022 to 6,197 in 2024, with provisional 2026 counts indicating further growth. The CDC’s urgent...
AI-driven imaging for clinical decision support
Researchers reported a preoperative AI model that predicts breast cancer recurrence risk before surgery using multimodal imaging inputs. The approach used deep learning radiomics from...
CAR-T control switch for solid tumor safety
Scientists developed CAR-T cells engineered with a synthetic genetic switch designed to activate therapeutic genes only upon contact with tumors. The approach targets a core solid-tumor...
Bioprocessing and scale-up: controlling lipid nanoparticles
MIT spin-out Bizon Labs emerged with a process-optimization strategy aimed at making lipid nanoparticle (LNP) manufacturing more reproducible at scale. The company said it focuses on physically...
AI-designed obesity therapeutics move from platform to preclinical programs
Zealand Pharma has signed a multi-target collaboration with Generate Biomedicines to design protein therapeutics for obesity and other metabolic diseases, using Generate’s generative AI and...
Funding: OrbiMed secures major new life-sciences capital for global investing
OrbiMed has raised $3 billion across two new life sciences funds, including more than $1 billion earmarked for Asia, according to the firm’s announcement. The new vehicle expands capital available...
Cell therapy manufacturing: rapid CAR-T expansion strategy aims to reduce turnaround risk
A manufacturing strategy from Portugal’s iBET and collaborators proposes “rapid manufacturing” for CAR T-cell products by limiting ex vivo expansion to three days or less. The approach is intended...
Drug development risk: Vanda pauses female-led Phase 3 program after late-stage failure
Vanda Pharmaceuticals is putting its social anxiety disorder program on hold after a late-stage trial failure in female patients. The company said the Phase 3 study, evaluating VQW-765, did not...
Clinical neuroscience: gene therapy and BBB-targeted strategies converge on CNS drug delivery
Two separate CNS-focused approaches are advancing with translational emphasis on reaching the brain and altering disease biology. First, a University of Cincinnati and UC Davis team reported AAV...
Oncology finance and pipeline competition: Verastem doubles down on KRAS-adjacent strategy
Verastem signaled strategic urgency in KRAS-driven cancers with new early clinical data and corporate moves. The company reported early promise for VS-7375 in small studies across metastatic...
Regulatory shift: EMA makes EU-level trial advice pilot permanent
The European Medicines Agency confirmed it will turn an EU-level trial advice pilot into a permanent option for sponsors. The change allows drug developers in the EU to continue seeking structured...
Molecular diagnostics: urine-based CXCL10 aims to flag kidney transplant rejection and infection at one year
A transplant-focused diagnostic concept centers on urine CXCL10 measurement to detect rejection and infection one year after transplantation. The underlying premise is that immune-cell recruitment...
Antimicrobial resistance: Iran’s carbapenem-resistant Klebsiella reaches half of clinical isolates
A landmark analysis of 46 studies reports that carbapenem-resistant Klebsiella pneumoniae now accounts for 51% of clinical isolates in Iran. The study further identifies blaOXA-48-like gene...
Discovery and platform: engineered Cas13a improvement targets HIV and other RNA viruses detection
Researchers at Rice University reported an improved Cas13a system designed to support detection of HIV and other RNA viruses in blood and environmental samples. Cas13a is an RNA-targeting...